TY - JOUR
T1 - Therapy operating characteristic curves
T2 - Tools for precision chemotherapy
AU - Barrett, Harrison H
AU - Alberts, David S.
AU - Woolfenden, James M.
AU - Caucci, Luca
AU - Hoppin, John W.
N1 - Funding Information:
The concepts introduced in this paper are rooted in gamma-rayimaging research supported by the National Institutes of Health under Grant Nos. R37EB000803 and P41 EB002035. Dr. Alberts was supported by the University of Arizona Cancer Center core under Grant No. P50 CA17094.
Publisher Copyright:
© 2016 Society of Photo-Optical Instrumentation Engineers (SPIE).
PY - 2016/4/1
Y1 - 2016/4/1
N2 - The therapy operating characteristic (TOC) curve, developed in the context of radiation therapy, is a plot of the probability of tumor control versus the probability of normal-tissue complications as the overall radiation dose level is varied, e.g., by varying the beam current in external-beam radiotherapy or the total injected activity in radionuclide therapy. This paper shows how TOC can be applied to chemotherapy with the administered drug dosage as the variable. The area under a TOC curve (AUTOC) can be used as a figure of merit for therapeutic efficacy, analogous to the area under an ROC curve (AUROC), which is a figure of merit for diagnostic efficacy. In radiation therapy, AUTOC can be computed for a single patient by using image data along with radiobiological models for tumor response and adverse side effects. The mathematical analogy between response of observers to images and the response of tumors to distributions of a chemotherapy drug is exploited to obtain linear discriminant functions from which AUTOC can be calculated. Methods for using mathematical models of drug delivery and tumor response with imaging data to estimate patient-specific parameters that are needed for calculation of AUTOC are outlined. The implications of this viewpoint for clinical trials are discussed.
AB - The therapy operating characteristic (TOC) curve, developed in the context of radiation therapy, is a plot of the probability of tumor control versus the probability of normal-tissue complications as the overall radiation dose level is varied, e.g., by varying the beam current in external-beam radiotherapy or the total injected activity in radionuclide therapy. This paper shows how TOC can be applied to chemotherapy with the administered drug dosage as the variable. The area under a TOC curve (AUTOC) can be used as a figure of merit for therapeutic efficacy, analogous to the area under an ROC curve (AUROC), which is a figure of merit for diagnostic efficacy. In radiation therapy, AUTOC can be computed for a single patient by using image data along with radiobiological models for tumor response and adverse side effects. The mathematical analogy between response of observers to images and the response of tumors to distributions of a chemotherapy drug is exploited to obtain linear discriminant functions from which AUTOC can be calculated. Methods for using mathematical models of drug delivery and tumor response with imaging data to estimate patient-specific parameters that are needed for calculation of AUTOC are outlined. The implications of this viewpoint for clinical trials are discussed.
KW - Therapy operating characteristic
KW - chemotherapy
KW - normal tissue complications
KW - positron emission tomography
KW - radiation therapy
KW - single-photon emission computed tomography
KW - tumor control
UR - http://www.scopus.com/inward/record.url?scp=85001515816&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85001515816&partnerID=8YFLogxK
U2 - 10.1117/1.JMI.3.2.023502
DO - 10.1117/1.JMI.3.2.023502
M3 - Article
AN - SCOPUS:85001515816
SN - 2329-4302
VL - 3
JO - Journal of Medical Imaging
JF - Journal of Medical Imaging
IS - 2
M1 - 023502
ER -